High fructose consumption is associated with insulin resistance and diabetic dyslipidemia, but the underlying mechanism is unclear. We show in hamsters that high fructose feeding stimulated FoxO1 production and promoted its nuclear redistribution in liver, correlating with augmented apoC-III production and impaired triglyceride metabolism. High fructose feeding upregulated PGC-1 and SREBP-1c expression, accounting for increased fat infiltration in liver. High fructose-fed hamsters developed hypertriglyceridemia, accompanied by hyperinsulinemia and glucose intolerance. These metabolic aberrations were reversible by fenofibrate, a commonly used anti-hypertriglyceridemia agent that is known to bind and activate PPAR-. PPAR-physically interacted with, but functionally antagonized FoxO1 in hepatic apoC-III expression. These data underscore the importance of FoxO1 deregulation in the pathogenesis of hypertriglyceridemia in high fructose-fed hamsters. Counter-regulation of hepatic FoxO1 activity by PPAR-constitutes an important mechanism by which fibrates act to curb apoC-III overproduction and ameliorate hypertriglyceridemia.
Introduction
Hypertriglyceridemia is characterized by increased production of very low-density lipoprotein (VLDL) and/or decreased clearance of TG-rich particles (4) . Due to its proatherogenic profile, hypertriglyceridemia is a major contributing factor for the pathogenesis of atherosclerosis and coronary artery disease in obesity and type 2 diabetes. While the pathophysiology of hypertriglyceridemia is poorly understood, its close association with visceral adiposity and type 2 diabetes implicates insulin resistance as a causative factor in the development of hypertriglyceridemia (5, 12, 22, 29, 42) . However, the molecular events that link insulin resistance to the pathogenesis of hypertriglyceridemia remain elusive.
An important player in plasma VLDL-TG metabolism is apolipoprotein C-III (apoC-III). It
functions as an inhibitor of lipoprotein lipase (LPL) and hepatic lipase, playing a pivotal role in the hydrolysis and clearance of TG-rich particles such as VLDL-TG and chylomicrons (27, 36, 51, 53) . Elevated plasma apoC-III levels are associated with impaired clearance of TG-rich particles, leading to the accumulation of TG-rich lipoprotein remnants in plasma and the development of hypertriglyceridemia.
Our recent data indicate that forkhead box O1 (FoxO1), a nuclear transcription factor known to be a mediator of insulin signaling, plays an important role in hepatic regulation of apoC-III.
FoxO1 stimulates hepatic apoC-III expression, which is counteracted by insulin (2) . Elevated FoxO1 production in liver augments hepatic apoC-III expression, resulting in increased plasma TG levels and impaired postprandial fat clearance in mice (2) . Transgenic mice expressing a FoxO1 constitutively active allele develop hypertriglyceridemia, as manifested by significantly Page 4 of 47 elevated plasma VLDL-TG levels and retarded postprandial fat clearance (2) . In insulin resistant states, hepatic FoxO1 activity becomes deregulated, culminating in elevated hepatic production along with skewed nuclear redistribution and accounting for its increased transactivation activity in liver (2, 3) . Furthermore, anti-sense oligonucleotide-mediated inhibition of FoxO1 activity improves hepatic and peripheral insulin action in high fat diet-induced obese mice (47) . These data implicate FoxO1 at the interface between impaired insulin action and aberrant apoC-III expression, contributing to the pathogenesis of hypertriglyceridemia in insulin resistant subjects.
Fibrates are commonly used as hypolipidemic agents for treating hypertriglyceridemia (13, 23, 33 ). An important function of fibrates is to suppress apoC-III production, contributing to increased VLDL-TG catabolism and decreased plasma TG levels (15, 16, 45, 52) . Fibrates bind and activate peroxisome proliferator-activated receptor alpha (PPAR-), a transcription factor that is abundantly expressed in liver (8, 21, 32, 37, 38) . However, it is conceptually difficult to reconcile fibrate-mediated activation of PPAR-activity with reduced apoC-III production and improved TG metabolism (24, 25, 28, 44) . Based on the findings that FoxO1 mediates the inhibitory effect of insulin on hepatic apoC-III expression and excessive FoxO1 activity may contribute to unrestrained apoC-III production and metabolic aberrations in diabetes (2), we hypothesized that fibrates would suppress FoxO1 expression and reduce apoC-III production, contributing to improved VLDL-TG metabolism.
We tested this hypothesis in high fructose-fed hamsters. Syrian golden hamsters develop hypertriglyceridemia accompanied by insulin resistance in response to high fructose feeding Page 5 of 47 (10, 14, 30) . But the underlying pathogenesis of high fructose-induced insulin resistance and hypertriglyceridemia remains elusive. To address the function of FoxO1 in hypertriglyceridemia and define the mechanism of fibrate action in triglyceride metabolism, we studied hepatic FoxO1 expression in hamsters fed high fructose diet vs. regular chow with and without fibrate treatment. We show that high fructose feeding augmented hepatic FoxO1 production and promoted its nuclear localization. This effect along with impaired insulin action contributes to apoC-III overproduction and the development of hypertriglyceridemia. High fructose feeding also resulted in marked induction of hepatic expression of PGC-1 (31), a coactivator of SREBP-1c, accounting for increased fat infiltration in liver. Fibrates upregulated hepatic production of PPAR-, which antagonized FoxO1 activity and corrected FoxO1 deregulation in liver, contributing to enhanced insulin sensitivity and the amelioration of hypertriglyceridemia in high fructose-fed hamsters. These data underscore the importance of FoxO1 deregulation in the pathogenesis of hypertriglyceridemia and illustrate a novel mechanism by which fibrates act to improve plasma VLDL-TG metabolism.
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Materials and Methods:
Animal studies: Syrian golden hamsters (male, 5-wk old, body weight of 81-90 g) were purchased from Charles River Laboratory (Wilmington, MA). Animals were fed with standard rodent chow and water ad libitum in sterile cages with a 12-h light/dark cycle. To induce hypertriglyceridemia, hamsters were fed a high fructose diet (60% fructose, 6% fat DYET #161506, Dyets Inc., Bethlehem, PA) for four weeks. For fibrate treatment, high fructoseinduced hamsters were randomly divided into two groups (n=9), which were treated with oncedaily oral gavage of 250-µl fenofibrate (50 mg/kg, Abbott Laboratories, Chicago, IL) or 250-µl saline as control. All hamsters were maintained on high fructose diet during a 4-week treatment. In addition, one group of hamsters fed regular rodent chow was used as normal control. Blood was collected from tail vein into capillary tubes pre-coated with potassium-EDTA (Sarstedt, Nümbrecht, Germany) for the preparation of plasma or the determination of blood glucose levels using Glucometer Elite (Bayer, IN). Plasma levels of TG and cholesterol were determined using Thermo Infinity TG and cholesterol reagents (Thermo Electron, Melbourne, Australia). Plasma free fatty acid (FFA) levels were determined using the Wako FFA assay kit (Wako Chemical USA, Richmond, VA). Plasma insulin levels were determined by anti-human insulin ELISA that cross-reacts with hamster insulin (ALPCO, Windham, NH).
At the end of study, animals were sacrificed by CO 2 inhalation and liver tissue were frozen in liquid N 2 . All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Children's Hospital of Pittsburgh (Protocol # 41-04).
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Glucose tolerance test: Hamsters were fasted for 5 h and injected intraperitoneally with 50% dextrose solution (Abbott Laboratories, Chicago) at 5 g/kg body weight. Blood glucose levels were determined and plotted as a function of time. Area under the curve (AUC) was calculated using the KaleidaGraph software (Synergy Software, Reading, PA).
Insulin sensitivity index:
Insulin sensitivity index (ISI) was calculated using the formula, ISI = 2/[(INS x GLU) + 1]. INS stands for fasting plasma insulin levels and GLU denotes fasting blood glucose levels, all values being converted to Pmol/L as described (7) . A similar homeostasis model assessment (HOMA) for calculating ISI has been described by Mattews et al. (35) . The principle of this formula is as follows; a reduction in insulin sensitivity results in elevated levels of either blood glucose or plasma insulin or both. ISI is a function of the compound effect of fasting blood glucose and plasma insulin levels. Preclinical and clinical data indicate that ISI correlates inversely with insulin resistance (6, 7, 35) .
Hepatic lipid content: 40 mg of liver tissue was homogenized in 800 µl of HPLC grade acetone. After incubation with agitation at room temperature overnight, aliquots (5 µl) of acetone-extract lipid suspension were used for the determination of TG concentrations using the Thermo Infinity TG reagent (Thermo Electron). Hepatic lipid content was defined as mg of TG per gram of liver tissue.
Western blot analysis: Isolation of nuclear proteins from homogenized liver tissue using the Pierce NE-PER extraction reagents (Pierce, Rockford, IL) has been described (2) . Aliquots (40 mg) of liver tissue were homogenized in 400 µl of ice-cold CER-I solution (Pierce) Page 8 of 47 supplemented with 4-µl protease inhibitor cocktail (Pierce). Nuclear fractions were separated from cytoplasm and subjected to immunoblot analysis using antibody against FoxO1, PPAR-, SREBP-1c, PGC-1 and -actin proteins as previously described (2) . The intensity of protein bands was quantified by densitometry using the NIH Image software (National Institutes of Health, Bethesda, MD) as described (2) . Polyclonal rabbit anti-FoxO1 antibody was developed in our laboratory by immunization of rabbits with the GST-tagged human FoxO1 protein (Genemed Synthesis Inc., San Francisco, CA). Rabbit anti-PGC-1 antibody was provided by Dr. Spiegelman's lab (31) . Antibodies against PPAR-(ABR Affinity BioReagents, Golden, CO), SREBP-1c (Cat. sc-13551, Santa Cruz Biotechnology, Santa Cruz, CA) and -actin (sc-1615, Santa Cruz Biotechnology) were commercially available. To determine plasma apoC-III levels, aliquots of plasma at a fixed quantity of protein (20 Pg) were blotted to a piece of nitrocellulose membrane by dot-blotting. The membrane was probed with goat anti-apoC-III antibody (1:1000 dilution, Abcam, Cambridge, MA), followed by incubation with rabbit antigoat IgG conjugated with peroxidase (1:6000 dilution, Jackson ImmunoResearch Laboratories, West Grove, PA). ApoC-III protein was detected using the ECL detection reagents (GE HealthCare), as described (2) . In addition, aliquots of plasma at a fixed concentration of 15-Pg proteins per lane were applied to 4-20% polyacrylamide gels. The gels were subjected to western blot assay using goat anti-apoC-III antibody (Abcam). ApoC-III proteins were visualized by ECL detection reagents and the relative intensities of protein bands were quantified by densitometry as described (2) . For the determination of hepatic MTP levels by the immunoblot assay, we have generated polyclonal anti-MTP antibody derived against a homologous region of MTP protein between rodents and humans (SYSASVKGHTTGLSLN, corresponding to MTP amino acid residues 14-29). After affinity purification by protein-A column chromatography, this MTP antibody (1:1000 dilution) reacted specifically with both rodent and human MTP proteins on western blots.
Immunoprecipitation:
Immunoprecipitation of FoxO1 from liver tissue by protein-A chromatography has been described (3). Aliquots of liver tissue (20 mg) were homogenized in 800 µl of M-PER buffer supplemented with 8-µl protease inhibitor cocktail (Pierce). After centrifugation at 13,000 rpm for 10 min in a microfuge, aliquots of protein lysates (600 µg)
were incubated with 5 µg of rabbit anti-FoxO1 antibody or preimmune serum for 1 h at room temperature. The samples were mixed with 80 µl of 50% protein-A slurry and incubated for 1 h at room temperature, followed by washing in 80 µl of 1xPBS containing 0.05% Tween-20 for three cycles, each 30 min. Immunoprecipitated proteins were eluted and analyzed on immunoblots using anti-FoxO1 and anti-PPAR-antibodies, respectively.
Immunoprecipitation of FoxO1-Q256 and PPAR-complex was performed. FoxO1-Q256 is a FoxO1 dominant-negative mutant that contains the amino domain (1-256 amino acid residues), as described (3, 39) . HepG2 were transfected with 4 µg of pPPAR-plasmid in Vitacell culture medium (American Type Culture Collection) in 6-well plates. 4 h later, culture media were renewed with pre-warmed media supplemented with adenoviral vector expressing FoxO1-Q256 at a multiplicity of infection of 100 pfu/cell as described (3). After 48-h incubation, cells were harvested and lysed in 100 µl of M-PER buffer supplemented with 1-µl protease inhibitor cocktail (Pierce). Protein lysates were subjected to immunoprecipitation by rabbit anti-FoxO1 antibody or preimmune serum as described above. Each condition was run Page 10 of 47 in triplicate. Immunoprecipitates were analyzed by immunoblot assay using anti-FoxO1 or anti-PPAR-antibody.
Effect of fenofibrate on FoxO1 and PPAR-interaction was determined as follows; HepG2 cells were co-transfected with FoxO1 and PPAR-expressing plasmids (2 µg each plasmid).
After 24 h of incubation, cells were incubated in the presence and absence of 50 mM fenofibrate in culture medium for 16 h, followed by immunoprecipitation using anti-FoxO1 antibody. Immunoprecipitated proteins were subjected to semi-quantitative immunoblot assay by anti-FoxO1 and anti-PPAR-antibodies, respectively.
FPLC fractionation of lipoproteins:
Aliquots (500 µl) of plasma were applied to two head-totail linked Tricorn high performance Superose S-6 10/300GL columns using an FPLC system (Amersham Biosciences), followed by elution with PBS at a constant flow rate of 0.5 ml/min.
Fractions (500 µl) were eluted and assayed for TG and cholesterol concentrations using the Thermo Infinity TG and cholesterol reagents (Thermo Electron).
Immunohistochemistry: Liver tissue from euthanized hamsters was embedded with Histoprep tissue embedding media (Fisher Scientific, NJ). Frozen sections were cut (8 µm) and subjected to immunohistochemistry using rabbit anti-FoxO1antibody (dilution at 1:1500). The second antibody was Cy3-conjugated goat anti-rabbit IgG (dilution 1:500, Jackson ImmunoResearch Laboratories, West Grove, PA). The nuclei of hepatocytes were visualized by staining with TO-PRO-3 dye (Molecular Probes Inc., Eugene, OR). Specimens were examined under a laser scanning confocal microscope (Nikon E800, Nikon Corporation, Japan).
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Liver histology: Liver tissue was embedded in the Histoprep tissue embedding media and snap-frozen. Frozen sections (8 µm) were cut for fat staining with Oil red O as described (19) .
Plasmid transfection and luciferase assay: HepG2 cells in 6-well microplates were transfected with 1-µg plasmid pHD317 encoding luciferase cDNA under the control of the human APOC3 promoter using the Lipofectamine 2000 (Invitrogen, Carlsbad, CA). In each transfection, 1-µg plasmid pCA35-LacZ was included and the amount of -gal activity was used as control for the normalization of transfection efficiency. After 48-hr incubation, cells were collected for luciferase and -gal activity assays as described (2) . After centrifugation at 13,000 rpm for 10 min, the supernatant was incubated with 8 µg of polyclonal rabbit anti-FoxO1 antibody, followed by immunoprecipitation using the ChIP kit (Upstate Biotechnology, Lake Placid, NY). As controls, aliquots (1x10 6 ) of pFoxO1-transfected or pFoxO1/pPPAR-co-transfected HepG2 cells were treated identically for the preparation of cell lysates, which were immunoprecipitated with 8 µg of preimmune rabbit IgG (Genemed Synthesis). The immunoprecipitated DNA was analyzed by PCR using 20-nt primers that flank -675/+1 nt of the APOC3 promoter as described (2) . PCR products were Page 13 of 47 analyzed on 1% agarose gels and the relative intensity of DNA bands were quantified by densitometry using the NIH Image software as described (2) .
To analyze the potential association between PPAR-and APOC3 promoter, HepG2 cells were transfected with 4 µg of pPPAR-DNA, followed by ChIP assay using monoclonal anti-PPAR-antibody (8 µg, ABR Affinity BioReagents) or 8 µg of preimmune rabbit IgG (Genemed Synthesis). Immunoprecipitates were analyzed by PCR using the APOC3 promoterspecific primers as described above.
Statistics: Statistical analyses of data were performed by analysis of variance (ANOVA) using StatView software (Abacus Concepts, Inc., CA). Pair-wise comparisons were performed to study the significance between different conditions. Data were expressed as the mean ± SEM. p-values < 0.05 are considered statistically significant.
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Results
Effect of fibrates on metabolism in high fructose-fed hamsters
Fibrates are commonly used oral agents for treating hypertriglyceridemia in subjects with obesity and type 2 diabetes, but their mechanisms of action are not completely understood. To define the molecular mechanism by which fibrates improve TG metabolism, we treated high fructose-induced hyperlipidemic hamsters with either an oral dose of fenofibrate or saline for 4 weeks, using one group of hamsters fed on regular chow as control. High fructose feeding did not result in significant alterations in blood glucose levels (Fig. 1A) . However, all hamsters fed on high fructose diet had significantly higher plasma insulin levels (Fig. 1B) , which is indicative of insulin resistance.
To corroborate this finding, we performed glucose tolerance test. Hamsters fed high fructose diet were associated with impaired abilities to tolerate intraperitoneally infused glucose ( Fig. 1 C and D). But in response to a 4-week treatment with fenofibrate, this impaired glucose tolerance along with elevated plasma insulin levels in high fructose-fed hamsters were restored to normal. Based on fasting blood glucose and plasma insulin levels, we calculated insulin sensitivity index (ISI) using a homeostasis model assessment as described (7) . As shown in Fig. 1E , high fructose-fed hamsters were associated with markedly reduced ISI, which was reversed to normal after 4-week treatment with fenofibrate. Fibrate treatment also resulted in a small reduction in body weight, but the mean body weight of fibrate-treated hamsters was not significantly different from regular chow-fed controls (Fig. 1F ).
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To determine the effect of high fructose diet on lipid metabolism, we determined plasma FFA, TG and total cholesterol levels. High fructose-fed hamsters are associated with significantly increased plasma FFA ( Fig. 2A) , TG (Fig. 2B ) and cholesterol levels (Fig. 2C) , when compared to hamsters fed regular chow. However, these aberrations in lipid metabolism were reversed to near normal after 4 weeks of treatment with fenofibrate.
Effect of fibrates on lipoprotein metabolism
To study the effect of fibrates on lipoprotein metabolism, we subjected plasma pooled from hamsters in individual groups to gel filtration chromatography for the fractionation of lipoproteins. In accordance with their elevated plasma TG levels, high fructose-fed hamsters exhibited significantly increased VLDL-TG levels (Fig. 2D) . The fractional concentrations of cholesterol in VLDL and HDL were also markedly increased in response to high fructose feeding (Fig. 2E) . After fenofibrate treatment, these elevated VLDL-TG levels were significantly ameliorated, but not restored to normal (Fig. 2D) . However, fenofibrate treatment reversed elevated VLDL-and HDL-cholesterol levels to normal (Fig. 2E ).
To gain insight into the molecular basis of fibrate-mediated beneficial effects on VLDL-TG metabolism, we determined the expression levels of apoC-III and microsomal triglyceride transfer protein (MTP), two functions that catalyze the rate-limiting steps in plasma VLDL-TG metabolism (26, 51) . Plasma apoC-III levels determined by both dot blot and western blot assays. These two approaches consistently show that plasma apoC-III levels were significantly increased in response to high fructose feeding, and were reduced to normal levels after 4-week fenofibrate treatment (Fig. 2F and 2G) . Likewise, hepatic MTP production was markedly induced in response to high fructose feeding, as detected by western blot analysis (Fig. 2H) .
Fenofibrate treatment suppressed excessive MTP production to normal levels in high fructosefed hamsters.
Hepatic lipid content in high fructose-fed hamsters in response to fibrate treatment
To investigate the metabolic consequence associated with high fructose feeding, liver tissue from euthanized hamsters was histologically examined after staining with Oil Red O. As shown in Fig. 3 A-C, significantly higher levels of lipid droplets were detected in livers of high fructose-fed hamsters. This observed increase in hepatic lipid deposition was confirmed by the quantification of overall hepatic fat content. Hamsters fed high fructose diet exhibited significantly higher levels of intrahepatic TG content (10.7ዊ0.8 mg/g vs. 6.3ዊ0.3 mg/g liver tissue in control diet-fed hamsters, p<0.001 by ANOVA) (Fig. 3D) . However, in response to fenofibrate treatment, this increased intrahepatic deposition in high fructose-fed hamsters was reduced to normal, as revealed by both histological examination and quantitative assay of fat content in liver.
To investigate the molecular mechanism underlying increased fat accumulation in livers of high fructose-fed hamsters, we determined the expression levels of two key transcription factors in hepatic lipid metabolism, SREBP-1c and its co-activator PGC-1 (31). Hepatic expression of both SREBP-1c (Fig. 4A ) and PGC-1 (Fig. 4B ) was significantly upregulated, coinciding with increased intrahepatic fat infiltration in high fructose-fed hamsters. After fenofibrate treatment, hepatic SREBP-1c and PGC-1 expression levels were suppressed to Page 17 of 47 normal, correlating with the reversal of hepatic fat content in fenofibrate-treated hamsters (Fig.   3 ).
Hepatic expression of FoxO1 in hyperlipidemic hamsters in response to fibrate treatment
To account for the mechanism of fenofibrate-mediated beneficial effect on hepatic TG metabolism, we determined hepatic FoxO1 abundance in high fructose-fed hamsters treated with fenofibrate. High fructose feeding resulted in >4-fold increase in hepatic FoxO1 protein levels, which were reduced to normal after a 4-week treatment with fenofibrate (Fig. 4C ).
As control, we studied hepatic expression profiles of PPAR-, the nuclear receptor of fibrates.
As shown in Fig. 4D , hepatic PPAR-protein levels remained at basal levels in high fructosefed hamsters. However, in response to a 4-week treatment with fenofibrate, hepatic PPARprotein levels were elevated by about 8 folds, which correlated inversely with hepatic FoxO1 expression in fenofibrate-treated hamsters (Fig. 4C) .
We have previously shown that hepatic FoxO1 activity becomes deregulated, culminating in increased nuclear localization in livers with impaired insulin action (2, 3). To determine the potential alterations in hepatic FoxO1 subcellular localization, we performed immunohistochemistry on liver tissue of sacrificed hamsters using anti-FoxO1 antibody. In comparison to regular chow-fed hamsters (Fig. 5 A-C) , FoxO1 was predominantly localized within the nucleus of hepatocytes in high fructose-fed hamsters (Fig. 5 D-F) . This skewed subcellular distribution of FoxO1 was reversed to normal in response to fenofibrate treatment (Fig. 5 G-I ).
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Functional interplay between FoxO1 and PPAR-in hepatic apoC-III expression
To study whether fenofibrate-mediated up-regulation of PPAR-expression in liver contributes to the inhibition of hepatic FoxO1 activity, we determined the potential interaction between FoxO1 and PPAR-proteins in liver. Liver tissue (20 mg) from fibrate-treated hamsters were homogenized and subjected to immunoprecipitation using rabbit anti-FoxO1 antibody or preimmune serum, followed by immunoblot analysis. As shown in Fig. 6A , we detected PPAR-protein in the product that was immunoprecipitated by anti-FoxO1 antibody, implicating a potential interaction between FoxO1 and PPAR-proteins in liver.
To corroborate this finding, we determined molecular association between PPAR-and To address whether FoxO1-PPAR-interaction is enhanced by fenofibrate, HepG2 cells were transfected with FoxO1 and PPAR-expressing plasmids. After 24-h incubation to allow FoxO1 and PPAR-production, cells were incubated in the presence and absence of 50 mM fenofibrate in culture medium for 16 h, followed by immunoprecipitation using anti-FoxO1 antibody. Using semi-quantitative immunoblot assay, we detected similar levels of PPARprotein in the immunoprecipitated complex of fenofibrate-and mock-treated cells (Fig. 6C) .
These results suggest that fibrates did not significantly enhance FoxO1 and PPARinteraction in HepG2 cells.
To address the functional interplay between FoxO1 and PPAR-in VLDL-TG metabolism, we studied the effect of FoxO1 on hepatic apoC-III production in the presence and absence of PPAR-production in HepG2 cells using a pre-defined human APOC3 promoter-directed luciferase reporter system (2). We have previously shown that FoxO1 stimulates human apoC-III expression via direct binding to its target site in the APOC3 promoter (2). As shown in Fig.   7A , such an APOC3 promoter-directed luciferase expression system in pHD317 was transfected to HepG2 cells that were pre-transfected with vectors expressing FoxO1 or PPARalone or both in combination. Consistent with our previous observations, FoxO1 markedly stimulated APOC3 promoter activity, as evidenced by significantly increased luciferase activity in response to elevated FoxO1 production in HepG2 cells (Fig. 7, B and C) . However, this stimulatory effect of FoxO1 on hepatic apoC-III expression was abolished in the presence of elevated PPAR-production (Fig. 7, B and C) . These results revealed a novel mechanism by which PPAR-counteracts the effect of FoxO1 on hepatic apoC-III expression in modulating plasma VLDL-TG metabolism.
To strengthen the above findings, we performed a similar study using a mutant version of the APOC3 promoter. As a result of mutations in the insulin responsive element (IRE), this mutant APOC3 promoter no longer responds to FoxO1 (2). We transfected this mutant promoterPage 20 of 47 directed luciferase expression system into HepG2 cells in the presence of FoxO1 or PPARexpression alone or both in combination. As shown in Fig. 7D , mutations in the IRE abolished FoxO1-mediated stimulation of APOC3 promoter activity and also abrogated PPAR-effect on ApoC-III expression in HepG2 cells. Furthermore, elevated PPAR-production alone did not result in significant changes in the mutant APOC3 promoter activity.
To address whether PPAR-suppresses FoxO1 expression at the transcriptional level, we cloned the 2-kb FoxO1 promoter using FoxO1 promoter-specific primers. After verification by DNA sequencing, the FoxO1 promoter was subcloned into a pGL3-basic luciferase reporter system. This FoxO1 promoter-directed luciferase expression system was transfected into HepG2 cells together with pPPAR-or control pGL3-basic plasmid, followed by analysis of luciferase activity after 24 h of incubation. As shown in Fig. 7E , PPAR-production resulted in a slight induction of FoxO1 promoter activity. In addition, we determined endogenous FoxO1 mRNA levels using semi-quantitative RT-PCR assay in PPAR-expressing and control cells. No significant difference in FoxO1 mRNA levels was detected in HepG2 cells that were transduced with either PPAR-or control plasmid (Fig. 7F) . These data indicate that PPAR-did not directly suppress hepatic FoxO1 expression.
Mechanism of PPAR-mediated antagonism of FoxO1 activity
To define the mechanism of PPAR-mediated counter-regulation of (Fig. 8A) . Using the same assay, we detected a similar APOC3 promoter-specific DNA in HepG2 cells expressing both FoxO1 and PPAR- (Fig. 8A) . But the relative amount of APOC3 promoter activity in FoxO1 and PPAR-co-expressing cells was >5-fold lower than in cells expressing FoxO1 alone, as determined by semi-quantitative PCR assay (Fig. 8B) . As control, no APOC3 promoter-specific DNA was detected when rabbit preimmune IgG was used in the ChIP assay (Fig. 8A) . FoxO1 stimulates hepatic apoC-III expression via specific binding to its target site (CCAAACA) in the APOC3 promoter DNA (2) . These data suggest that this association between FoxO1 and APOC3 promoter DNA was significantly reduced in response to PPAR-production, which correlated with the inhibition of APOC3 promoter activity in PPAR-expressing HepG2 cells (Fig. 7, B and C) .
To investigate whether PPAR-alone binds to APOC3 promoter DNA, we subjected pPPARexpressing HepG2 cells to ChIP assay using anti-PPAR-antibody, followed by PCR analysis using the same set of APOC3 promoter-specific primers as described (Fig. 8A) . No specific PCR DNA was produced. While PPAR-is known to bind specifically to a highly conserved DNA sequence that comprises 2-hexamer repeats with one nucleotide in between (AGGTCAXAGGTCA) in target promoters (11) , sequence analysis did not reveal the presence of such a consensus PPAR-binding site within a 5-kb DNA region of the APOC3 promoter (-5000/+1 nt). These data were consistent with the lack of significant alterations in APOC3 promoter activity in response to PPAR-production in HepG2 cells (Fig. 7, B and C) , suggesting that PPAR-modulates hepatic apoC-III expression by counteracting the stimulatory effect of FoxO1 on APOC3 promoter activity (2) .
Discussion
The goal of this study is to determine the role of FoxO1 in the pathogenesis of hypertriglyceridemia and address whether FoxO1 mediates the beneficial effect of fibrates on VLDL-TG metabolism in high fructose-fed hamsters. We show that high fructose feeding resulted in marked elevations in plasma FFA, TG and total cholesterol levels, accompanied by significantly elevated plasma insulin levels and impaired glucose tolerance. Interestingly, fasting blood glucose levels and body weight remained unchanged in high fructose-fed hamsters. These data indicate that hamsters fed high fructose diet, as opposed to regular chow, developed insulin resistance and hypertriglyceridemia in the absence of fasting hyperglycemia and excessive body weight gain. Thus, high fructose-fed hamsters represent a nonobese model of insulin resistance with altered TG metabolism.
Our present studies indicate that hepatic FoxO1 activity becomes deregulated, culminating in markedly elevated production along with increased nuclear localization in livers of high fructose-fed hamsters. Similar observations have been made in insulin resistant livers of high fat-induced obese mice (unpublished data) and diabetic db/db mice (2, 3). These data unveil an association between hepatic FoxO1 deregulation and impaired hepatic metabolism. Indeed,
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FoxO1 gain-of-function, as a result of adenovirus-mediated hepatic FoxO1 production or transgenic expression of its constitutively active allele in liver, is associated with impaired glucose metabolism in mice (40, 46) . Conversely, FoxO1 loss-of-function, caused by hepatic expression of its dominant-negative allele in insulin resistant liver, is associated with significantly improved fasting glycemia and amelioration of hyperinsulinemia in diabetic db/db mice (3). FoxO1 haploinsufficiency is sufficient to protect mice from developing high fatinduced insulin resistance (41) and rescue the diabetic phenotype in insulin receptor substrate 2 (IRS2)-deficient diabetic mice (43) . Furthermore, targeted FoxO1 inhibition by anti-sense approach improved hepatic metabolism and peripheral insulin action in high fat diet-induced obesity (47) . While high fructose feeding is associated with hypertriglyceridemia, the underlying mechanism remains elusive. Our present data suggest that aberrant hepatic FoxO1 function is a contributing factor for metabolic abnormalities in high fructose-fed hamsters.
Consistent with this interpretation is the revelation that plasma apoC-III levels were significantly elevated, correlating with increased hepatic FoxO1 activity in high fructose-fed hamsters. We have previously shown that FoxO1 mediates the inhibitory effect of insulin on hepatic apoC-III expression and FoxO1 deregulation links loss of insulin inhibition to unrestrained apoC-III production, contributing to the pathogenesis of hypertriglyceridemia (2).
This predicts that a selective inhibition of FoxO1 activity will suppress apoC-III production in high fructose-fed hamsters. Indeed, we show that hepatic FoxO1 deregulation was corrected in high fructose-fed hamsters in response to fenofibrate treatment. This effect parallels the normalization of plasma apoC-III levels and amelioration of hypertriglyceridemia in fenofibrate-treated hamsters. Thus, modification of FoxO1 transcriptional activity represents an Page 24 of 47 important mechanism by which fibrates curb apoC-III overproduction and improve TG metabolism in subjects with hypertriglyceridemia.
In addition to FoxO1, we observed that multiple factors such as PGC-1 and SREBP-1c contribute to high fructose-induced hypertriglyceridemia. A co-activator of SREBP-1c, PGC-1 has been shown to bind and augment SREBP-1c transcription activity in stimulating lipogenesis, contributing to elevated hepatic VLDL-TG production and secretion, and the development of hyperlipidemia in high fat-induced obese mice (31) . Likewise, we detected a significant increase in hepatic fat content in high fructose-fed hamsters, which correlated with augmented hepatic PGC-1 and SREBP-1c expression. These observations along with the induction of hepatic MTP production help explain previous observations that high fructose-fed hamsters are associated with inappropriately increased hepatic VLDL-TG production (10).
Increased fat infiltration in organs other than adipose tissue, such as liver and skeletal muscle, is closely associated with insulin resistance (9, 17, 29, (48) (49) (50) 54) . Our present findings provide important insights into the mechanism of fructose-induced insulin resistance, suggesting that an increased intrahepatic lipid deposition plays a causative role in the development of insulin resistance, as reflected in hyperinsulinemia and glucose intolerance in high fructose-induced hamsters. In keeping with this conclusion, we show that fenofibrate treatment suppressed hepatic PGC-1 and SREBP-1c expression to basal levels, resulting in the normalization of hepatic fat content in high fructose-fed hamsters. These data suggest that fenofibrate-mediated suppression of PGC-1 and SREBP-1c expression also contributes to the reversal of insulin resistance and amelioration of hypertriglyceridemia in high fructose-fed hamsters.
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Although it is known that hepatic PPAR-activity is upregulated by fibrates (8, 13, 21) , the molecular link between upregulated PPAR-activity and improved triglyceride metabolism remains undefined. We show in high fructose-fed hamsters that PPAR-and FoxO1 are differentially regulated by fibrates. Hepatic PPAR-levels were significantly increased, accompanied by a corresponding decrease in hepatic FoxO1 levels in fenofibrate-treated hyperlipidemic hamsters. While inappropriately increased FoxO1 activity in liver is associated with abnormal hepatic metabolism (1, 34, 46) In addition to its activation of PPAR- (21, 32, 37, 38) , fenofibrate has been shown to display pleiotropic effects on the expression of genes in lipid metabolism. Fibrates upregulate lipoprotein lipase (LPL) expression (18, 21) . This effect along with the suppression of apoC-III overproduction accounts for enhanced clearance of lipoprotein remnants. Furthermore, fibrates are shown to enhance carnitine palmitoyltransferase I (CPT1) expression, accounting for increased fatty acid oxidation in liver and muscle, and contributing to improved insulin sensitivity (37) .
Increased consumption of fructose, a major ingredient of corn syrup used in soft drinks, is associated with the development of insulin resistance and dyslipidemia, but the underlying mechanism is unknown. Our studies highlight the importance of hepatic FoxO1 deregulation along with augmented PGC-1 production in the pathogenesis of high fructose-induced insulin resistance and hypertriglyceridemia, and furthermore elucidate a novel molecular antagonism of PPAR-against FoxO1 in mediating the effect of fibrates on the reversal of hypertriglyceridemia. These data provide evidence that selective inhibition of FoxO1 activity in liver can be explored as a distinctive mechanism for better management of hypertriglyceridemia. PPAR-alone or both in combination, using pCA35-LacZ as control. Each condition was run in triplicate. Cells were subjected to luciferase and -gal activity assay after 24-h incubation.
E: Effect of PPAR-on FoxO1 promoter activity. The FoxO1 promoter-directed luciferase expression system pFoxO-luc was co-transfected with pPPAR-or control pGL3-basic plasmid (2 µg per plasmid) in 6-well plates using pCA35-LacZ (1 Pg) as control. After 24-h incubation, cells were collected for the determination of luciferase and -gal activities. Data were from three independent experiments. # p<0.05. F: Effect of PPAR-on FoxO1 mRNA expression: A subset of HepG2 cells from panel E experiment was used for the preparation of total RNA, which was analyzed by RT-PCR using specific primers corresponding to FoxO1, PPAR-and -actin cDNA. Quantification of PCR products. The relative amounts of PCR products corresponding to the specific APOC3 promoter DNA were quantified by densitometry. Results were obtained from three independent experiments. *p<0.001.
